-
1
-
-
0034889092
-
The management of coumarin-induced over-anticoagulation Annotation
-
Makris, M.; Watson, H.G. The management of coumarin-induced over-anticoagulation Annotation. Br. J. Haematol. 2001, 114, 271-280.
-
(2001)
Br. J. Haematol
, vol.114
, pp. 271-280
-
-
Makris, M.1
Watson, H.G.2
-
2
-
-
11244284872
-
Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism
-
King, B.P.; Khan, T.I.; Aithal, G.P.; Kamali, F.; Daly, A.K. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics 2004, 14, 813-822.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 813-822
-
-
King, B.P.1
Khan, T.I.2
Aithal, G.P.3
Kamali, F.4
Daly, A.K.5
-
3
-
-
38049181030
-
Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues
-
Gage, B.F.; Lesko, L.J. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 2008, 25, 45-51.
-
(2008)
J. Thromb. Thrombolysis
, vol.25
, pp. 45-51
-
-
Gage, B.F.1
Lesko, L.J.2
-
4
-
-
8244250134
-
Hemorrhagic complications of oral anticoagulant therapy: Results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)
-
Palareti, G.; Leali, N.; Coccheri, S.; Poggi, M.; Manotti, C.; D'Angelo, A.; Pengo, V.; Erba, N.; Moia, M.; Ciavarella, N.; Devoto, G.; Berretini, M.; Musolesi, S. Hemorrhagic complications of oral anticoagulant therapy: Results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G. Ital. Cardiol. 1997, 27, 231-243.
-
(1997)
G. Ital. Cardiol
, vol.27
, pp. 231-243
-
-
Palareti, G.1
Leali, N.2
Coccheri, S.3
Poggi, M.4
Manotti, C.5
D'Agelo, A.6
Pengo, V.7
Erba, N.8
Moia, M.9
Ciavarella, N.10
Devoto, G.11
Berretini, M.12
Musolesi, S.13
-
5
-
-
0035814973
-
Clinical trials that have influenced the treatment of venous thromboembolism: A historical perspective
-
Hirsh, J.; Bates, S.M. Clinical trials that have influenced the treatment of venous thromboembolism: A historical perspective. Ann. Intern. Med. 2001, 134, 409-417.
-
(2001)
Ann. Intern. Med
, vol.134
, pp. 409-417
-
-
Hirsh, J.1
Bates, S.M.2
-
6
-
-
0035128503
-
Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
-
Hirsh, J.; Dalen, J.; Anderson, D.R.; Poller, L.; Bussey, H.; Ansell, J.; Deykin, D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001, 119, 8S-21S.
-
(2001)
Chest
, vol.119
-
-
Hirsh, J.1
Dalen, J.2
Anderson, D.R.3
Poller, L.4
Bussey, H.5
Ansell, J.6
Deykin, D.7
-
7
-
-
77952389622
-
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin
-
Jones, D.R.; Kim, S.Y.; Guderyon, M.; Yun, C.H.; Moran, J.H.; Miller, G.P. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem. Res. Toxicol. 2010, 23, 939-945.
-
(2010)
Chem. Res. Toxicol
, vol.23
, pp. 939-945
-
-
Jones, D.R.1
Kim, S.Y.2
Guderyon, M.3
Yun, C.H.4
Moran, J.H.5
Miller, G.P.6
-
8
-
-
77951898626
-
Pharmacogenetics of warfarin
-
Kamali, F.; Wynne, H. Pharmacogenetics of warfarin. Annu. Rev. Med. 2010, 61, 63-75.
-
(2010)
Annu. Rev. Med
, vol.61
, pp. 63-75
-
-
Kamali, F.1
Wynne, H.2
-
9
-
-
0031015345
-
Human P450 metabolism of warfarin
-
Kaminsky, L.S.; Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73, 67-74.
-
(1997)
Pharmacol. Ther
, vol.73
, pp. 67-74
-
-
Kaminsky, L.S.1
Zhang, Z.Y.2
-
10
-
-
10344266522
-
Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation
-
Adcock, D.M.; Koftan, C.; Crisan, D.; Kiechle, F.L. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch. Pathol. Lab. Med. 2004, 128, 1360-1363.
-
(2004)
Arch. Pathol. Lab. Med
, vol.128
, pp. 1360-1363
-
-
Adcock, D.M.1
Koftan, C.2
Crisan, D.3
Kiechle, F.L.4
-
11
-
-
0034872136
-
Pharmacogenetics of warfarin elimination and its clinical implications
-
Takahashi, H.; Echizen, H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. 2001, 40, 587-603.
-
(2001)
Clin. Pharmacokinet
, vol.40
, pp. 587-603
-
-
Takahashi, H.1
Echizen, H.2
-
12
-
-
0028210729
-
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
-
Rettie, A.E.; Wienkers, L.C.; Gonzalez, F.J.; Trager, W.F.; Korzekwa, K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4, 39-42.
-
(1994)
Pharmacogenetics
, vol.4
, pp. 39-42
-
-
Rettie, A.E.1
Wienkers, L.C.2
Gonzalez, F.J.3
Trager, W.F.4
Korzekwa, K.R.5
-
13
-
-
0030587544
-
Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
-
Haining, R.L.; Hunter, A.P.; Veronese, M.E.; Trager, W.F.; Rettie, A.E. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 1996, 333, 447-458.
-
(1996)
Arch. Biochem. Biophys
, vol.333
, pp. 447-458
-
-
Haining, R.L.1
Hunter, A.P.2
Veronese, M.E.3
Trager, W.F.4
Rettie, A.E.5
-
14
-
-
0030868485
-
Genetic association between sensitivity to warfarin and expression of CYP2C93
-
Steward, D.J.; Haining, R.L.; Henne, K.R.; Davis, G.; Rushmore, T.H.; Trager, W.F.; Rettie, A.E. Genetic association between sensitivity to warfarin and expression of CYP2C93. Pharmacogenetics 1997, 7, 361-367.
-
(1997)
Pharmacogenetics
, vol.7
, pp. 361-367
-
-
Steward, D.J.1
Haining, R.L.2
Henne, K.R.3
Davis, G.4
Rushmore, T.H.5
Trager, W.F.6
Rettie, A.E.7
-
15
-
-
0033694203
-
Genetic modulation of oral anticoagulation with warfarin
-
Margaglione, M.; Colaizzo, D.; D'Andrea, G.; Brancaccio, V.; Ciampa, A.; Grandone, E.; Di Minno, G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 2000, 84, 775-778.
-
(2000)
Thromb. Haemost
, vol.84
, pp. 775-778
-
-
Margaglione, M.1
Colaizzo, D.2
D'Adrea, G.3
Brancaccio, V.4
Ciampa, A.5
Grandone, E.6
di Minno, G.7
-
16
-
-
0036914221
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
-
Scordo, M.G.; Pengo, V.; Spina, E.; Dahl, M.L.; Gusella, M.; Padrini, R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 2002, 72, 702-710.
-
(2002)
Clin. Pharmacol. Ther
, vol.72
, pp. 702-710
-
-
Scordo, M.G.1
Pengo, V.2
Spina, E.3
Dahl, M.L.4
Gusella, M.5
Padrini, R.6
-
17
-
-
0842269293
-
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9 2 or CYP2C93 alleles on acenocoumarol or phenprocoumon
-
Visser, L.E.; van Vliet, M.; van Schaik, R.H.; Kasbergen, A.A.; De Smet, P.A.; Vulto, A.G.; Hofman, A.; van Duijn, C.M.; Stricker, B.H. The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004, 14, 27-33.
-
(2004)
Pharmacogenetics
, vol.14
, pp. 27-33
-
-
Visser, L.E.1
van Vliet, M.2
van Schaik, R.H.3
Kasbergen, A.A.4
de Smet, P.A.5
Vulto, A.G.6
Hofman, A.7
van Duijn, C.M.8
Stricker, B.H.9
-
18
-
-
72949108032
-
Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance
-
Wang, B.; Wang, J.; Huang, S.Q.; Su, H.H.; Zhou, S.F. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Curr. Drug. Metab. 2009, 10, 781-834.
-
(2009)
Curr. Drug. Metab
, vol.10
, pp. 781-834
-
-
Wang, B.1
Wang, J.2
Huang, S.Q.3
Su, H.H.4
Zhou, S.F.5
-
19
-
-
0029564238
-
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
-
Furuya, H.; Fernandez-Salguero, P.; Gregory, W.; Taber, H.; Steward, A.; Gonzalez, F.J.; Idle, J.R. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995, 5, 389-392.
-
(1995)
Pharmacogenetics
, vol.5
, pp. 389-392
-
-
Furuya, H.1
Fernandez-Salguero, P.2
Gregory, W.3
Taber, H.4
Steward, A.5
Gonzalez, F.J.6
Idle, J.R.7
-
20
-
-
0033608466
-
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
-
Aithal, G.P.; Day, C.P.; Kesteven, P.J.; Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353, 717-719.
-
(1999)
Lancet
, vol.353
, pp. 717-719
-
-
Aithal, G.P.1
Day, C.P.2
Kesteven, P.J.3
Daly, A.K.4
-
21
-
-
0037012465
-
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
-
Higashi, M.K.; Veenstra, D.L.; Kondo, L.M.; Wittkowsky, A.K.; Srinouanprachanh, S.L.; Farin, F.M.; Rettie, A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287, 1690-1698.
-
(2002)
JAMA
, vol.287
, pp. 1690-1698
-
-
Higashi, M.K.1
Veenstra, D.L.2
Kondo, L.M.3
Wittkowsky, A.K.4
Srinouanprachanh, S.L.5
Farin, F.M.6
Rettie, A.E.7
-
22
-
-
0036194038
-
The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin
-
Tabrizi, A.R.; Zehnbauer, B.A.; Borecki, I.B.; McGrath, S.D.; Buchman, T.G.; Freeman, B.D. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 2002, 194, 267-273.
-
(2002)
J. Am. Coll. Surg
, vol.194
, pp. 267-273
-
-
Tabrizi, A.R.1
Zehnbauer, B.A.2
Borecki, I.B.3
McGrath, S.D.4
Buchman, T.G.5
Freeman, B.D.6
-
23
-
-
0034283762
-
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
-
Taube, J.; Halsall, D.; Baglin, T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000, 96, 1816-1819.
-
(2000)
Blood
, vol.96
, pp. 1816-1819
-
-
Taube, J.1
Halsall, D.2
Baglin, T.3
-
24
-
-
1342332251
-
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
-
Wadelius, M.; Sorlin, K.; Wallerman, O.; Karlsson, J.; Yue, Q.Y.; Magnusson, P.K.; Wadelius, C.; Melhus, H. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2004, 4, 40-48.
-
(2004)
Pharmacogenomics J
, vol.4
, pp. 40-48
-
-
Wadelius, M.1
Sorlin, K.2
Wallerman, O.3
Karlsson, J.4
Yue, Q.Y.5
Magnusson, P.K.6
Wadelius, C.7
Melhus, H.8
-
25
-
-
0033884635
-
Cytochrome P450 polymorphisms are associated with reduced warfarin dose
-
Freeman, B.D.; Zehnbauer, B.A.; McGrath, S.; Borecki, I.; Buchman, T.G. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000, 128, 281-285.
-
(2000)
Surgery
, vol.128
, pp. 281-285
-
-
Freeman, B.D.1
Zehnbauer, B.A.2
McGrath, S.3
Borecki, I.4
Buchman, T.G.5
-
26
-
-
0141832724
-
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
-
Takahashi, H.; Echizen, H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J. 2003, 3, 202-214.
-
(2003)
Pharmacogenomics J
, vol.3
, pp. 202-214
-
-
Takahashi, H.1
Echizen, H.2
-
27
-
-
0030468137
-
Lung cancer risk in relation to the CYP2C91/CYP2C92 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California
-
London, S.J.; Daly, A.K.; Leathart, J.B.; Navidi, W.C.; Idle, J.R. Lung cancer risk in relation to the CYP2C91/CYP2C92 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996, 6, 527-533.
-
(1996)
Pharmacogenetics
, vol.6
, pp. 527-533
-
-
London, S.J.1
Daly, A.K.2
Leathart, J.B.3
Navidi, W.C.4
Idle, J.R.5
-
28
-
-
0030868490
-
Genetic analysis of CYP2C9 polymorphism in a Japanese population
-
Nasu, K.; Kubota, T.; Ishizaki, T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997, 7, 405-409.
-
(1997)
Pharmacogenetics
, vol.7
, pp. 405-409
-
-
Nasu, K.1
Kubota, T.2
Ishizaki, T.3
-
29
-
-
0030947801
-
Allelic and functional variability of cytochrome P4502C9
-
Bhasker, C.R.; Miners, J.O.; Coulter, S.; Birkett, D.J. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997, 7, 51-58.
-
(1997)
Pharmacogenetics
, vol.7
, pp. 51-58
-
-
Bhasker, C.R.1
Miners, J.O.2
Coulter, S.3
Birkett, D.J.4
-
30
-
-
38749112521
-
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins
-
Schalekamp, T.; Klungel, O.H.; Souverein, P.C.; de Boer, A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch. Intern. Med. 2008, 168, 180-185.
-
(2008)
Arch. Intern. Med
, vol.168
, pp. 180-185
-
-
Schalekamp, T.1
Klungel, O.H.2
Souverein, P.C.3
de Boer, A.4
-
31
-
-
32944479043
-
SSRIs and upper gastrointestinal bleeding: What is known and how should it influence prescribing?
-
Dalton, S.O.; Sorensen, H.T.; Johansen, C. SSRIs and upper gastrointestinal bleeding: What is known and how should it influence prescribing? CNS Drugs 2006, 20, 143-151.
-
(2006)
CNS Drugs
, vol.20
, pp. 143-151
-
-
Dalton, S.O.1
Sorensen, H.T.2
Johansen, C.3
-
32
-
-
1842688880
-
Incidence and determinants of long-term use of antidepressants
-
Meijer, W.E.; Heerdink, E.R.; Leufkens, H.G.; Herings, R.M.; Egberts, A.C.; Nolen, W.A. Incidence and determinants of long-term use of antidepressants. Eur. J. Clin. Pharmacol. 2004, 60, 57-61.
-
(2004)
Eur. J. Clin. Pharmacol
, vol.60
, pp. 57-61
-
-
Meijer, W.E.1
Heerdink, E.R.2
Leufkens, H.G.3
Herings, R.M.4
Egberts, A.C.5
Nolen, W.A.6
-
33
-
-
0031694830
-
Drug interactions with newer antidepressants: Role of human cytochromes P450
-
Greenblatt, D.J.; von Moltke, L.L.; Harmatz, J.S.; Shader, R.I. Drug interactions with newer antidepressants: Role of human cytochromes P450. J. Clin. Psychiatry 1998, 59 (Suppl. 15), 19-27.
-
(1998)
J. Clin. Psychiatry
, vol.59
, Issue.SUPPL. 15
, pp. 19-27
-
-
Greenblatt, D.J.1
von Moltke, L.L.2
Harmatz, J.S.3
Shader, R.I.4
-
34
-
-
0032424283
-
Differential pharmacology of newer antidepressants
-
DeVane, C.L. Differential pharmacology of newer antidepressants. J. Clin. Psychiatry 1998, 59 (Suppl. 20), 85-93.
-
(1998)
J. Clin. Psychiatry
, vol.59
, Issue.SUPPL. 20
, pp. 85-93
-
-
Devane, C.L.1
-
35
-
-
72949087810
-
The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients
-
Hauta-Aho, M.; Tirkkonen, T.; Vahlberg, T.; Laine, K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann. Med. 2009, 41, 619-628.
-
(2009)
Ann. Med
, vol.41
, pp. 619-628
-
-
Hauta-Aho, M.1
Tirkkonen, T.2
Vahlberg, T.3
Laine, K.4
-
36
-
-
67649389950
-
Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment
-
Wallerstedt, S.M.; Gleerup, H.; Sundstrom, A.; Stigendal, L.; Ny, L. Risk of clinically relevant bleeding in warfarin-treated patients-influence of SSRI treatment. Pharmacoepidemiol. Drug Saf. 2009, 18, 412-416.
-
(2009)
Pharmacoepidemiol. Drug Saf
, vol.18
, pp. 412-416
-
-
Wallerstedt, S.M.1
Gleerup, H.2
Sundstrom, A.3
Stigendal, L.4
Ny, L.5
-
37
-
-
33645046396
-
Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: A multicentre retrospective analysis
-
Wessinger, S.; Kaplan, M.; Choi, L.; Williams, M.; Lau, C.; Sharp, L.; Crowell, M.D.; Keshavarzian, A.; Jones, M.P. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: A multicentre retrospective analysis. Aliment. Pharmacol. Ther. 2006, 23, 937-944.
-
(2006)
Aliment. Pharmacol. Ther
, vol.23
, pp. 937-944
-
-
Wessinger, S.1
Kaplan, M.2
Choi, L.3
Williams, M.4
Lau, C.5
Sharp, L.6
Crowell, M.D.7
Keshavarzian, A.8
Jones, M.P.9
-
38
-
-
0031969526
-
Antidepressant interactions with warfarin
-
Duncan, D.; Sayal, K.; McConnell, H.; Taylor, D. Antidepressant interactions with warfarin. Int. Clin. Psychopharmacol. 1998, 13, 87-94.
-
(1998)
Int. Clin. Psychopharmacol
, vol.13
, pp. 87-94
-
-
Duncan, D.1
Sayal, K.2
McConnell, H.3
Taylor, D.4
-
39
-
-
0033798922
-
Psychotropic interactions with warfarin
-
Sayal, K.S.; Duncan-McConnell, D.A.; McConnell, H.W.; Taylor, D.M. Psychotropic interactions with warfarin. Acta Psychiatr. Scand. 2000, 102, 250-255.
-
(2000)
Acta Psychiatr. Scand
, vol.102
, pp. 250-255
-
-
Sayal, K.S.1
Duncan-McCnnell, D.A.2
McConnell, H.W.3
Taylor, D.M.4
-
40
-
-
0031035097
-
Effect of sertraline on protein binding of warfarin
-
Apseloff, G.; Wilner, K.D.; Gerber, N.; Tremaine, L.M. Effect of sertraline on protein binding of warfarin. Clin. Pharmacokinet. 1997, 32 (Suppl. 1), 37-42.
-
(1997)
Clin. Pharmacokinet
, vol.32
, Issue.SUPPL. 1
, pp. 37-42
-
-
Apseloff, G.1
Wilner, K.D.2
Gerber, N.3
Tremaine, L.M.4
|